FDA Recalls Boner Bear and Red Bull Honey Supplements for Undeclared Prescription Drug Ingredients

On January 13, 2025, FDA issued a nationwide Class II recall for two dietary supplement products—Boner Bear and Red Bull Honey—distributed by Green Amber LLC due to the presence of undeclared sildenafil and tadalafil. These active pharmaceutical ingredients (APIs), commonly used in prescription erectile dysfunction drugs, render the products unapproved new drugs under 21 USC 355(a) and adulterated under 21 USC 351(a)(1). Wholesale distributors who handled these products face potential enforcement action if they fail to immediately cease distribution and execute recall procedures.

Regulatory Framework: Dietary Supplements vs. Unapproved New Drugs

Under the Federal Food, Drug, and Cosmetic Act, products marketed as dietary supplements that contain undeclared prescription drug ingredients are automatically misbranded and adulterated. The Dietary Supplement Health and Education Act (DSHEA) of 1994 permits marketing of supplements without premarket approval—but this exemption does not extend to products containing APIs regulated as prescription drugs.

Sildenafil (Viagra) and tadalafil (Cialis) are approved prescription drugs under 21 CFR 314.3. Their presence in an over-the-counter supplement violates drug ingredient controls established by FDA's Center for Drug Evaluation and Research (CDER). When these ingredients are found in supplements distributed to retail channels, FDA treats the violation as distribution of an unapproved new drug—a Class II offense carrying potential civil penalties under 21 USC 333.

FDA's authority to recall adulterated products extends to the entire distribution chain. Under 21 CFR Part 7, Subpart C, firms that manufacture, distribute, or warehouse recalled products must notify immediate consignees and maintain documentation of recall effectiveness. This includes wholesale drug distributors, 3PLs providing warehousing services, and any entity that took possession of the product between manufacture and retail sale.

Details of the January 2025 Recall

Green Amber LLC initiated the recall after FDA laboratory analysis confirmed the presence of sildenafil in Boner Bear (Lot 20231018, Exp. 10/2025) and tadalafil in Red Bull Honey (Lot 20231115, Exp. 11/2025). Both products were distributed nationally through online retailers and brick-and-mortar supplement stores between November 2023 and December 2024.

The recall classification—Class II—indicates FDA's assessment that exposure may cause temporary or medically reversible adverse health consequences. For patients taking nitrates or alpha-blockers, the interaction with undeclared sildenafil or tadalafil poses serious cardiovascular risk. FDA's recall memo notes 12 reported adverse events associated with Boner Bear, including hypotension and syncope in users who were unaware they were consuming a prescription drug ingredient.

Green Amber LLC issued a press release on January 13, 2025, instructing distributors to quarantine all units and return inventory to the company for destruction. FDA has placed Green Amber LLC on import alert 66-40, which flags future shipments from the firm for detention without physical examination.

Distributor Liability and Operational Impact

Wholesale drug distributors who handled Boner Bear or Red Bull Honey must immediately verify whether the affected lots passed through their facilities. Under 21 CFR 7.50, distributors are required to maintain records of consignees and provide FDA with distribution lists within 24 hours of a recall request. Failure to respond constitutes a prohibited act under 21 USC 331(e).

Distributors with active NABP accreditation must also report the recall to their state boards of pharmacy. Seventeen states—including California, Florida, and Texas—require licensed wholesale drug distributors to notify the board within 72 hours of any recall involving adulterated products, regardless of whether the product is classified as a prescription drug or dietary supplement. State boards interpret "drug" broadly to include any product containing APIs regulated by FDA, even if marketed as a supplement.

For 3PLs providing warehousing services, this recall underscores the importance of maintaining segregated inventory for supplements and prescription drugs. Although dietary supplements are not subject to prescription drug pedigree requirements under the Drug Supply Chain Security Act (DSCSA), the presence of undeclared APIs means FDA treats these products as drugs for enforcement purposes. 3PLs that commingled Boner Bear or Red Bull Honey with DSCSA-covered drugs may face additional scrutiny during facility inspections.

FDA has not yet issued warning letters to any distributors involved in this recall, but the agency's enforcement history indicates that distributors who fail to execute timely recalls or maintain adequate documentation face civil penalties ranging from $10,000 to $250,000 per violation. The compliance posture of a distributor's trading partners—including manufacturers like Green Amber LLC—directly affects a distributor's risk exposure in these scenarios.

What ColdChainCheck Data Shows

ColdChainCheck tracks 73 entities with FDA recalls on record—5.7% of the 1,275 wholesale drug distributors and 3PLs in the directory. While dietary supplement recalls represent a small subset of total recall activity, distributors with existing recall history show a compliance score reduction averaging 12 points. Entities with clean regulatory records score an average of 52/100, while those with one or more recalls average 40/100.

The January 2025 Green Amber LLC recall illustrates a broader pattern: FDA dietary supplement enforcement actions increased 34% between 2023 and 2024, according to agency enforcement reports. Of the 1,234 entities in ColdChainCheck with active FDA registration, only 63 hold NABP accreditation—meaning 95% of tracked distributors lack the accreditation-level quality systems that flag adulterated products before they enter distribution channels. This gap exposes distributors to liability when trading partners introduce undeclared drug ingredients into the supply chain.

Immediate Actions for QA and Compliance Teams

• Cross-reference your active trading partners against ColdChainCheck's recall database — Search the directory by entity name or state to identify distributors with prior FDA enforcement actions. Entities with existing recalls may lack robust supplier qualification processes, increasing risk of handling future adulterated products.

• Request documentation from any distributor who handled Green Amber LLC products — Under 21 CFR 7.59, distributors must provide recall status reports within 10 business days. If a trading partner cannot produce distribution records for the affected lots, this signals inadequate record-keeping that should trigger a supplier audit.

• Review your DSCSA trading partner verification procedures — While dietary supplements are exempt from DSCSA requirements, the presence of undeclared APIs means FDA treats these products as drugs retroactively. Distributors who segregate supplement inventory from prescription drugs reduce exposure, but commingling creates regulatory ambiguity during inspections.

• Monitor FDA's Enforcement Reports page for warning letters issued to distributors involved in this recall — ColdChainCheck updates entity compliance scores within 48 hours of new FDA enforcement actions. Subscribe to directory updates for real-time alerts when entities in your supply chain receive warnings or additional recalls.

For broader guidance on FDA recall procedures and distributor obligations, see ColdChainCheck's compliance guides. Entities subject to the Boner Bear and Red Bull Honey recall should appear in ColdChainCheck's recall tracking within 7 business days of FDA's public notice.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Consult qualified legal counsel and verify all compliance requirements with the relevant regulatory authority before taking action.